Novo Nordisk NVO Drops 8% to $43.83 as Competition and Legal Troubles Mount

The shares opened the session at $47.62 before a sharp mid-day break sent them down to $43.83, an 8% decline that trimmed the company's market value to $147 billion. That figure is a steep comedown from the peak valuation Novo Nordisk once commanded as the undisputed leader in GLP-1 obesity drugs, a crown that is increasingly being contested.

The pressure is coming from two directions at once. Rivals are crowding the GLP-1 space with competing weight-loss therapies, squeezing the pricing power and market-share dominance that had made Novo Nordisk one of the most valuable companies in Europe. At the same time, a shareholder lawsuit tied to its next-generation weight-loss drug is adding legal and reputational uncertainty on top of the competitive headwinds.

For investors, the key question now is whether $43.83 represents a floor or a way station on a deeper retreat. The stock's intraday chart shows the bulk of the damage arrived in a single swift leg lower, which can sometimes signal forced selling rather than a reassessment of fundamentals — but the dual pressures of intensifying competition and active litigation give the market concrete reasons to stay cautious.